微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 41.97% | 2.84% | 2.58% | 90/157 | 50.55% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 40.92% | -9.96% | 0.38% | 90/157 | 50.61% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 40.76% | -8.25% | -2.27% | 91/157 | -2.2% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 41.71% | -9.73% | 2.2% | 89/157 | 14.83% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 40.81% | -9.2% | -10.19% | 90/157 | 31.96% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 45.45% | -2.11% | 2.29% | 88/157 | 51.88% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 44.43% | -9.13% | -3.84% | 88/157 | 22.51% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 46.2% | -9.04% | 2.79% | 86/157 | 33.12% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 44.95% | -17.59% | -3.18% | 86/157 | 51.76% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 46.43% | -5.4% | -5.04% | 89/157 | 51.61% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 48.89% | 1.44% | -3.75% | 80/157 | 32.47% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 50.79% | 6.31% | -6.87% | 75/157 | 38.42% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 54.54% | 21.06% | 11.14% | 68/157 | 52.97% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 49.07% | 3.02% | 1.82% | 85/157 | 53.83% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 48.2% | -0.97% | 0.88% | 81/157 | 5.64% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 47.78% | -8.84% | 6.05% | 84/157 | 20.99% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 45.05% | -18.13% | -5.42% | 80/157 | 54.39% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 47.63% | 3.54% | -2.13% | 87/157 | 55.2% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 48.67% | 0.5% | -7.13% | 77/157 | 46.77% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 52.41% | 7.11% | -4.77% | 75/157 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 55.03% | 8.7% | 19.62% | 64/157 | 54.13% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 46.01% | -6.94% | -5% | 90/157 | -148.64% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 48.43% | 6.52% | -1.02% | 70/157 | 56.43% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 48.93% | 12.13% | -3.35% | 72/157 | 54.17% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 50.63% | 19.3% | 2.4% | 63/157 | 55.17% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 49.44% | -2.77% | 8.74% | 79/157 | -1242.15% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 45.46% | -5.99% | 4.19% | 67/157 | 55.23% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 43.63% | -10.57% | 2.83% | 73/157 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 42.43% | -17.8% | -16.55% | 69/157 | 51.07% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 50.85% | 36.79% | 5.15% | 68/157 | -211.97% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 48.36% | 53.17% | -0.88% | 56/157 | 54.14% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 48.79% | 64.74% | -5.48% | 56/157 | 53.53% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 51.62% | 81.49% | 38.87% | 53/157 | 54.16% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 37.17% | 26.61% | 17.74% | 83/157 | 52.55% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 31.57% | 5.12% | 6.6% | 73/157 | 49.09% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 29.62% | 1.23% | 4.13% | 81/157 | 47.91% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 28.44% | 48.55% | -3.12% | 65/157 | 46.94% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 29.36% | 81.46% | -2.25% | 88/157 | 48.46% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 30.04% | 77.4% | 2.66% | 62/157 | 46.19% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 29.26% | 79.2% | 52.8% | 71/157 | 46.26% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 19.15% | 33.89% | 18.34% | 74/157 | 43.86% | 贝达药业 | 97.01% | 行业排名> |